Quadriplegia Treatment Market is expected to grow at a CAGR of 4.1% during the forecast period : FMI

According to the latest research by Future Market Insights, quadriplegia treatment market is expected to grow at a CAGR of 4.1% during the forecast period. The demand for quadriplegia treatment will progressively rise, which will provide manufacturers with numerous favorable development opportunities in the near future. 

To remain ‘ahead’ of your competitors, request for a sample @
https://www.futuremarketinsights.com/reports/sample/rep-gb-14232 

What are the key Drivers of Quadriplegia Treatment Market?

Quadriplegia is caused by spinal cord injury which is caused due to trauma at the base of the neck or skull. Some of the common causes of quadriplegia, otherwise known as tetraplegia are paralysis after any accident, tumors of the spinal cord or other spinal cord diseases. The injury to the spinal cord may cause partial or total limb paralysis.

According to 2020 data sheet of Spinal Cord Injury Statistics, it was estimated that approximately 17,810 new cases of spinal cord injuries occur every year in the U.S. Some of the reasons for quadriplegia include stroke, vehicular accidents, falls, violence, sports, medical or surgical causes and others.

According to WHO statistics, published in June 2021, 20-50 million people suffer from road traffic accidents every year which lead to non-fatal injuries yet permanent disabilities to them. With the increasing rate of road traffic accidents, the demand for quadriplegia treatment is set to show a positive growth over the forecast period.

Recent technological advancements and various R&D activities in the field of quadriplegia treatment are one of the leading causes which will boost the demand for this market in forthcoming years. There is an increased level of awareness amongst the patients suffering from spinal cord injuries about various treatment options available to improve their quality of life. This is another factor which will propel the demand for various treatments for quadriplegia during the forecast market.

Electrical Stimulation: Revolutionary Technique that Got Quadriplegic People Back on their Feet.

Electrical stimulators which were originally designed to treat chronic pain helped more than a dozen patients with quadriplegia to wiggle their toes, flex their legs or even walk with support.

This was a revolutionary technique which was conducted in the lab of University of Louisville in Kentucky. Electrical stimulation thus made promising and huge gains for people with paralysis wanting to regain their functionalities. The study was published in July 2019, after which thousands of patients have enrolled in the wait lists for the electrical stimulation technique.

U.S. and Canada Quadriplegia Treatment: Regional Outlook

U.S. and Canada region was found to be the largest market for the diagnosis and treatment of spinal cord injury (SCI). Increasing awareness and advanced technologies are the main drivers of this market. Most of the accidents found that alcohol was one of the most important factors; that is, approximately 25% of spinal cord injuries.

In the United States, the average annual medical cost for treating an acute spinal cord injury has been found to be in the range of $ 15,000 to $ 30,000 per year. All these factors are expected to drive the market growth of quadriplegia treatment market and offer lucrative opportunities for the providers.

Europe Quadriplegia Treatment: Regional Outlook

Europe was observed to be the second largest market, region wise for the quadriplegia treatment industry. Some of the factors contributing to this large market share are the presence of leading research institutes in the region for various neurological disease diagnosis and treatment. Increased awareness regarding various new technologies which help the quadriplegic patients lead a relatively normal life is also another key driver for this industry in Europe.

Who are the key player of Quadriplegia Treatment Market?

Major manufacturers of medications needed to treat quadriplegia are

  • Merck & Co.
  • Sanofi Pharmaceuticals
  • Baxter International
  • Zydus Cadila
  • GlaxoSmithKline
  • AstraZeneca
  • Cipla
  • Johnson & Johnson
  • Bristol Myers Squibb Co.
  • Eli Lily & Co.
  • Teva Pharmaceuticals
  • Takeda Pharmaceutical Co Ltd
  • Hoffmann La Roche
  • Sun Pharmaceuticals.

In November 2020, Pfizer and Mylan announced the merger of Pfizer’s Upjohn generics unit and Mylan. This deal was a part of restructuring drive at Pfizer, which was aimed for stronger foothold in the innovative medicines division of the company.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

For critical insights on this market, request to ask an expert here @
https://www.futuremarketinsights.com/ask-question/rep-gb-14232 

Quadriplegia Treatment Market Report Highlights:

  • Shifting Industry dynamics.
  • In-depth market segmentation.
  • Historical, current and projected industry size recent industry trends.
  • Key Competition landscape.
  • Strategies for key players and product offerings.
  • Potential and niche segments/regions exhibiting promising growth.
  • A neutral perspective towards market performance.

Note: Although care has been taken to maintain the highest levels of accuracy in reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Key Segments 

By Treatment Type:

  • Corticosteroids
  • Non- Steroidal Anti-inflammatory Drugs (NSAIDs)
  • Antidepressants
    • Selective serotonin reuptake inhibitors (SSRIs)
    • Serotonin and norepinephrine reuptake inhibitors (SNRIs)
  • Anticonvulsants
  • Narcotic Analgesics
  • Antispasmodics & Muscle Relaxants
  • Antibiotics

By Route of Administration:

  • Oral
  • Intravenous
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Stores?

For More Information or Query or Customization Before Buying, Visit:
https://www.futuremarketinsights.com/customization-available/rep-gb-14232 

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • MEA

Leave a comment

Your email address will not be published.